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Mucosal melanomas account for 0.5–2.0% of all
melanomas and anorectal melanomas account for  less
than 25% of all mucosal melanomas [1–8]. Anorectal
melanoma is a rare, lethal neoplasm and frequently
arises from melanocytes of the anal squamous zone
distal to the dentate line [9–12]. They typically present
in the fifth or sixth decade of life and predominantly
in woman. Patients have initial local symptoms like
rectal bleeding and a changed defecation pattern
[1,3–6,12,13]. These symptoms can interfere with
benign conditions such as hemorrhoids and polyps.
Here, we reviewed the morphological and clinical
features of 14 anorectal melanomas.
METHODS
The clinical and pathological records of 14 patients
who were diagnosed with anorectal malignant
melanoma between 1997 and 2004 were reviewed.
The clinical features of the patients at the time of
admission and follow-up information were obtained
from hospital records or directly from the patients’
families. Patients were evaluated with regard to age,
sex, histopathological findings, treatment modality
and survival. We defined survival as the time that
elapsed between initial diagnosis and death attribut-
able to carcinoma. Histopathological findings were
obtained from surgically resected specimens from
files in the Department of Pathology. Histological
sections of formalin-fixed, paraffin-embedded material
stained with hematoxylin and eosin were reviewed to
assess tumor size, cell type, pigmentation and lymph
node or distant metastasis. Tumor cells were classi-
fied as epithelioid, lymphoma-like, spindle cell, or
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Anorectal melanomas represent a group of mucosal melanomas with unknown etiology and poor
prognosis. The lesions can be misdiagnosed as hemorrhoids during clinical examination. We
reviewed the morphological and clinical features of 14 anorectal melanomas, and discuss the
treatment modalities of this entity. Fourteen patients who were diagnosed with anorectal malignant
melanoma between 1997 and 2004 were evaluated with regard to age, sex, size, morphology, lymph
node or distant metastasis, treatment modality and survival. Eight patients were female and six
were male, and their mean age was 58 years. The size of melanoma ranged from 3 cm to 8 cm.
Pathological evaluation revealed epithelioid and spindle cell type tumor in seven and two patients,
respectively, whereas, in the remaining seven patients, the tumor was composed of both types.
Pigmentation was apparent in all tumors. There was lymph node metastasis in 11 patients and
distant metastasis in all patients. Eleven patients underwent abdominoperineal resection and
three were treated by local excision. Mean survival was 8.7 months. Prognosis of anorectal
melanoma remains poor. Awareness of the diverse clinicopathological features of these lesions,
both on the part of the clinicians and pathologists, is crucial for their early detection and proper
treatment.
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pleomorphic. Pigmentation was graded as present 
or absent. The treatment modality was based both on
the clinical stage that was assessed by digital rectal
examination and surgeons’ preference.
RESULTS
The clinical features at initial diagnosis and follow-up
for all 14 cases are given in the Table. The mean age
was 58 years (range, 27–75 years). Eight patients were
female and six were male. The most common presen-
tation was rectal bleeding (7 cases), followed by pain
(5 cases), changes in bowel habits (2 cases), and anal
mass (8 cases). The size of melanoma ranged from
3 cm to 8 cm (mean = 4.4 cm). All patients were diag-
nosed preoperatively with malignant melanoma by
colonoscopic biopsy.
Eleven patients were treated with abdominoper-
ineal resection (APR) and three with local excision
(LE). There was lymph node metastasis in 11 patients
and distant metastasis in all patients; liver and brain
were the most affected sites. Seven patients received
adjunctive therapy including radiotherapy and che-
motherapy. All patients died of the disease during
follow-up. Mean survival was 8.7 months (range,
3–29 months).
Histopathologically, two cell types were observed:
epithelioid and spindle cell. Pathological evaluation
revealed epithelioid and spindle cell type tumor in
seven and two patients, respectively, whereas, in the
remaining seven patients, tumor was composed of
both cell types. Lymphoma-like or pleomorphic type
was not encountered. Epithelioid-type tumor cells
usually formed granular cytoplasm, and enlarged,
irregular and often angulated nuclei. Nuclear mem-
branes were irregularly thickened with vesicular chro-
matin. Nucleoli were large and often eosinophilic
(Figure A). Spindle tumor cells generally did not dis-
play vesicular chromatin patterns or prominent nucle-
oli. They had enlarged, elongated, somewhat angulated
nuclei with diffuse hyperchromasia (Figure B). Pig-
mentation was apparent in all tumors. The malignant
cell population showed strong and diffuse immuno-
histochemical staining for S-100 protein in all cases
(Figure C). The majority of cases stained with HMB-45,
although there was greater variability in the strength
and distribution (Figure D).
DISCUSSION
Melanocytes migrate as neuroectodermal derivatives
in the ectodermally-derived mucosa, and can be found
in the mucous membranes of the upper aerodigestive
(mouth, nose, and paranasal sinuses), gastrointesti-
nal (anorectum, esophagus, stomach and gallbladder),
and urogenital (vagina, penis and urethra) tracts
[1,10,14–17]. Some of these cells show an age-related
increase, with a large number of them being found at
Table. Clinical and pathological features of cases
Case
Age (yr)/
Symptom
Size Cell
Pigment
LN Distant
Treatment
Follow-up Survey
sex (cm) type metastasis metastasis outcome (mo)
1 70/F B, P 3 × 3 × 2 E + + Brain APR DOD 9
2 55/M M, P 5 × 5 × 2.5 E + + Brain APR DOD 4
3 66/F M 4 × 4 × 1 E + S + + Liver APR + RT DOD 10
4 60/F C 5 × 5 × 3 E + S + + Brain, lung – DOD 5
5 43/M B, P 5 × 5 × 2.5 E + + Brain, liver APR + CT + RT DOD 6
6 55/F B, M 3 × 2 × 2 S + + Liver LE + CT DOD 29
7 66/F M 3 × 3 × 2.5 E + S + + Liver, lung APR + CT + RT DOD 13
8 63/M B 7 × 6 × 3 E + + Brain APR DOD 3
9 52/M M, P 6 × 6 × 5 E + − Brain, liver APR + CT + RT DOD 3
10 27/M B 8 × 5.5 × 3.5 E + S + + Brain, lung APR + CT + RT DOD 4
11 67/F M 3 × 2 × 2 S + + Liver LE DOD 13
12 75/M M 3 × 3 × 2 E + − Brain LE DOD 12
13 73/F B, P 5 × 4 × 3 E + − Liver APR DOD 13
14 61/F B, C, M 3 × 3 × 2 E + S + + Brain, lung APR + CT DOD 3
LN = lymph node; B = bleeding; P = Pain; E = Epithelioid; APR = abdominoperineal resection; DOD = died of disease; M = mass;
S = spindle; RT = radiotherapy; C = change in bowel habits; CT = chemotherapy; LE = local excision.
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or beyond the seventh decade of life in both sexes
[12,18]. These cells give rise to malignant melanomas
of the mucous membranes. Although both cutaneous
and extracutaneous melanomas arise from trans-
formed melanocytes, they differ substantially in clin-
icopathological and molecular aspects. This probably
reflects the lack of association with sun damage, fam-
ily history, familial predisposition, genes, and precur-
sor nevi in extracutaneous melanomas [1,12,19,20].
Contrary to cutaneous melanomas that usually dis-
seminate to regional lymph nodes, extracutaneous
melanomas disseminate hematogenously to the liver,
skin, lung and brain [12]. This frequent vascular inva-
sion is associated with tumor necrosis, aggressive
behavior and poor prognosis [12]. Das et al reported
that most patients (48/72; 66%) presented with distant
metastases. Nineteen patients (19/24) had positive
lymph node disease, and the mean disease-free sur-
vival in these patients was 10.3 months. Disease-free
survival in the node-negative patients was 26.5
months [21].
Patients present with rectal bleeding, painful 
defecation, change in bowel habits and pigmented or
non-pigmented polypoid masses that prolapse through
the anal verge, with the same presentation as hemor-
rhoids [9,12]. The tumor is frequently mistaken for
benign conditions such as hemorrhoids or rectal pol-
yps [22,23]. Magnetic resonance imaging and endo-
scopic ultrasonography have been shown to be useful
in making an earlier and more accurate diagnosis
[22,23]. On computed tomography scans, anal mel-
anoma appears as a bulky, intraluminal fungating
mass in the distal rectum, which focally expands and
obscures the lumen without causing obstruction,
with perirectal infiltration and frequently enlarged
lymph nodes [22,23].
The ideal treatment for anorectal melanoma
remains controversial, with 90% of patients dying
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Figure. Tumors demonstrated considerable morphological variability, including (A) epithelioid type and (B) spindle cell type (hema-
toxylin and eosin; original magnification, 200×). Immunohistochemical evaluation demonstrated strong staining for (C) S–100 and
(D) HMB–45 (original magnification, 400×).
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irrespective of the surgical approach or adjuvant
radiotherapy and chemotherapy [12]. The role of adju-
vant radiotherapy, immunotherapy and chemother-
apy in this disease has not been established. Adjuvant
therapies have been used after surgical resection in
some studies, with no strong evidence of improvement
in outcome [4,24]. Surgical treatment of this specific
tumor has a wide spectrum that varies from conser-
vative treatment such as LE, to radical operations
such as APR. [4–8,19,25]. In a review that included 17
large case series, Yap et al compared the survival of
patients who underwent APR or LE. The analysis
revealed no statistically significant difference between
two treatment modalities, even at all stages of the
disease [26]. Moozar et al reported a better survival
rate in patients who underwent wide excision when
compared with LE in a study of 14 patients [27]. In
our study, 11 patients underwent APR and three were
treated by LE, but there was no difference with respect
to survival in both groups.
These non-cutaneous malignant melanomas are
rare tumors with aggressive behavior and dismal
outcome [1,11]. The prognosis of patients is poor: the
5-year survival rate is estimated at between 6% and
22% [3,28,29]. The median survival of patients with
anorectal melanomas in the United States is 10 months
for those with distant metastasis, 13 months for those
with regional spread, and 34 months for those with
localized disease [28]. Twenty to sixty-two percent of
patients with anorectal melanomas have metastatic
disease at the time of initial diagnosis as a result of the
rich lymphatic system of the anorectal region [12,30].
The tumor can disseminate after a latent period of
2–20 years to several sites such as lymph nodes, bone,
lungs, liver, spleen, gastrointestinal tract, kidneys,
adrenal glands and subcutaneous tissue [1,11].
The most important prognostic indicators in
anorectal melanoma include age, sex, size, anatomic
site, stage of disease, duration of symptoms, nodal
involvement and molecular markers like proliferat-
ing cell nuclear antigen and Ki67 [6]. The Clark level
and Breslow indexes that are used for evaluation of
cutaneous malignant melanomas are not applicable to
extracutaneous malignant melanomas [12]. However,
tumor thickness seems to be a strong predictive factor
for the risk of local recurrences, as reported by Ballo
et al in 2002 [31]. In this respect, anorectal melanoma
seems to be similar to cutaneous melanoma, for which
tumor thickness is used to plan therapeutic procedures.
Invasion into the submucosa gives the tumor cells
access to lymphovascular channels, which help in their
dissemination [6]. Owing to the rarity of the tumor
and its histological variability, misdiagnosis is common;
particularly in amelanotic cases with unusual mor-
phological features that can be mistaken for lym-
phoma, carcinoma, and/or sarcoma [13]. Histologically,
the tumor can mimic adenocarcinoma, small cell car-
cinoma and sarcoma, and the lesion often mimics
hemorrhoids [29].
In conclusion, anorectal melanoma is a rare and
challenging disease. It affects mostly older patients
and has a female predominance. It differs from cuta-
neous melanoma with regard to risk. The preoperative
staging has an important role in influencing treatment
decisions, however, according to our experience, the
type of surgery does not alter the natural history of
this disease. Quality of life needs to be considered
when making treatment decisions.
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